Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nanosonics Limited ( (AU:NAN) ) just unveiled an update.
Nanosonics Limited announced a change in the director’s interest, specifically involving Mr. Michael Kavanagh. The change pertains to the issuance of 59,233 Service Rights under the Nanosonics Equity Plan, reflecting the company’s ongoing commitment to aligning executive interests with shareholder value. This adjustment in securities is part of the company’s broader strategy to incentivize and retain key personnel, which could have implications for its operational focus and stakeholder engagement.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited operates in the healthcare industry, specializing in infection prevention solutions. The company is known for its innovative technologies, particularly in the area of ultrasound probe disinfection, and focuses on enhancing patient safety and reducing hospital-acquired infections.
Average Trading Volume: 601,075
Technical Sentiment Signal: Sell
Current Market Cap: A$1.21B
Learn more about NAN stock on TipRanks’ Stock Analysis page.